-+ 0.00%
-+ 0.00%
-+ 0.00%
Chrysos (ASX:C79) Shares Enter A New Phase With Profit At Last
Share
Listen to the news

Chrysos stock comes into this earnings read on a strong run, with the shares up about 41% over the past month and sitting at A$7.78 at the last close. That kind of run up suggests that expectations were already intense.

The headline from the FY26 result is simple. Chrysos is now a profitable, cash-generative assay technology business with revenue of about A$88.1m and earnings from continuing operations of A$1.79m over the last twelve months. The emotional tug of a high P/S of 10.2x now collides with a business that is starting to put real profit behind the story.

Love the strong share price run and Chrysos turning profitable, but uneasy about paying a 10.2x P/S for it? Take a look at our curated list of 9 high quality undervalued stocks for alternatives that pair solid fundamentals with more grounded valuations.

FY 2026 Earnings Summary

  • Revenue FY 2026: A$88.1m vs. FY 2025 A$66.2m (up 33%)
  • Net Income from Continuing Operations FY 2026: A$1.79m vs. FY 2025 loss of A$8.22m (returned to profit)
  • Basic EPS FY 2026: Loss of A$0.0421 per share vs. FY 2025 loss of A$0.0713 per share (smaller loss per share)
  • EBITDA FY 2026: A$27.2m vs. FY 2025 A$16.2m (up 68%)

Prefer clear charts over another wall of earnings tables and ratios? See Chrysos' full financial picture with an easy visual view of its valuation in our company report for Chrysos.

ASX:C79 Trailing 12-Month Earnings & Revenue History as at Aug 2026
ASX:C79 Trailing 12-Month Earnings & Revenue History as at Aug 2026

Chrysos results keep the growth story on track

For investors leaning bullish on Chrysos, the latest figures support the idea of a maturing mining tech platform. Revenue of A$88.1m and EBITDA of A$27.2m both moved ahead of operating costs, which helped the company report earnings from continuing operations of A$1.79m. Cash from operations of A$17.9m and a largely contracted revenue base through Minimum Monthly Assay Payments suggest the core PhotonAssay model is gaining traction across regions without stretching the balance sheet.

Where Chrysos risks still warrant investor caution

The bear story is not fully resolved. Basic EPS remains in loss territory at A$0.0421 per share, which shows that depreciation, financing and non cash items still weigh on statutory profitability. Capital intensity is also clear, with A$36.3m of growth capex and a A$200m facility that increases financial obligations if deployment or sample volumes slow. Execution risk around unit roll out and site readiness therefore stays central to the near term risk profile, even as current trends look favourable.

After capital intensive years and recent insider selling, could these pressures be early warnings of deeper issues? Review our risk analysis for Chrysos which shows 2 important warning signs

Stay Ahead With Simply Wall St

If the recent profitability shift and high P/S multiple at Chrysos have your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and spot a price level that fits your plan. After you own the stock, use the Portfolio Command Center to cut through noise and keep on top of the most important updates to your holdings. For longer term conviction building, tap into crowd insights through the Community and see how other investors are thinking about the same risks and opportunities. By surfacing potential catalysts and pressure points early, Simply Wall St helps you stay ahead of the market and act with more confidence.

Seeking Alternatives Beyond Chrysos Stock

Fresh ideas do not stay under the radar for long. Spot potential breakout momentum and shifting interest while it matters, before prices get caught flying away from you. Act now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending